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Background
Patients with genotype 1 hepatitis C virus (HCV) who do not have a sustained response 
to therapy with peginterferon alfa and ribavirin have a low likelihood of success with 
retreatment.
Methods
We randomly assigned patients with HCV genotype 1 who had not had a sustained 
virologic response after peginterferon alfa–ribavirin therapy to one of four treat-
ment groups: 115 patients to the T12PR24 group, receiving telaprevir (1125-mg load-
ing dose, then 750 mg every 8 hours) for 12 weeks and peginterferon alfa-2a (180 μg 
per week) and ribavirin (1000 or 1200 mg per day, according to body weight) for 24 
weeks; 113 patients to the T24PR48 group, receiving telaprevir for 24 weeks and 
peginterferon alfa-2a and ribavirin for 48 weeks (at the same doses as in the T12PR24 
group); 111 patients to the T24P24 group, receiving telaprevir and peginterferon 
alfa-2a for 24 weeks (at the same doses as in the T12PR24 group); and 114 patients 
to the PR48 (or control) group, receiving peginterferon alfa-2a and ribavirin for 48 
weeks (at the same doses as in the T12PR24 group). The primary end point was 
sustained virologic response (undetectable HCV RNA levels 24 weeks after the last 
dose of study drugs).
Results
The rates of sustained virologic response in the three telaprevir groups — 51% in the 
T12PR24 group, 53% in the T24PR48 group, and 24% in the T24P24 group — were 
significantly higher than the rate in the control group (14%; P<0.001, P<0.001, and 
P = 0.02, respectively). Response rates were higher among patients who had previously 
had relapses than among nonresponders. One of the most common adverse events in 
the telaprevir groups was rash (overall, occurring in 51% of patients, with severe rash 
in 5%). Discontinuation of study drugs because of adverse events was more frequent in 
the telaprevir groups than in the control group (15% vs. 4%).
Conclusions
In HCV-infected patients in whom initial peginterferon alfa and ribavirin treatment 
failed, retreatment with telaprevir in combination with peginterferon alfa-2a and riba-
virin was more effective than retreatment with peginterferon alfa-2a and ribavirin 
alone. (ClinicalTrials.gov number, NCT00420784.)
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W orldwide, an estimated 170 mil-lion people have chronic hepatitis C virus (HCV) infection, and in many of 
these people, cirrhosis and complications of end-
stage liver disease will develop.1,2 Chronic HCV 
infection is the leading cause of liver disease and 
is the leading indication for liver transplanta-
tion in the United States and Europe.3 Currently 
available treatment for HCV infection necessi-
tates peginterferon alfa injections combined with 
oral ribavirin for 24 or 48 weeks (depending on 
the HCV genotype).4 Overall, in 40 to 50% of 
patients infected with HCV genotype 1 who 
have not previously been treated, the currently 
available treatment results in short- and longer-
term benefits associated with sustained virologic 
response.5-11 For patients in whom a sustained 
virologic response is not achieved, retreatment 
options are limited to reexposure to the same 
medications, with potential modification of the 
dose or duration of the regimen. These retreat-
ment strategies are associated with clinically 
significant morbidity and generally have a very 
limited chance of resulting in a successful out-
come.11,12 Therefore, the development of effec-
tive regimens to retreat patients with chronic HCV 
infection who did not have a sustained response 
to previous therapy is an urgent priority.
Telaprevir, an orally bioavailable inhibitor of 
the nonstructural 3/4A (NS3/4A) HCV protease,13 
is one of several investigational agents that spe-
cifically targets HCV with the goal of improving 
the chance of a sustained virologic response. In 
two recent phase 2, multicenter studies of tel-
aprevir in combination with peginterferon alfa-
2a and ribavirin in patients infected with HCV 
genotype 1 who had not previously been treated, 
the addition of telaprevir for 12 weeks, as part 
of a combination regimen with a total duration 
of 24 weeks in most patients, significantly in-
creased the rates of sustained virologic response, 
albeit with more patients in the telaprevir group 
than in the control group discontinuing thera-
py because of adverse events.14,15 In the current 
study, we aimed to assess the safety and effi-
cacy of telaprevir-based therapy in patients with 
HCV infection who had not had a sustained re-
sponse to an initial full course of treatment with 
peginterferon alfa and ribavirin.
Me thods
Study Conduct
An independent data and safety monitoring com-
mittee evaluated the rates of viral breakthrough 
and the safety and tolerability of the study drugs on 
the basis of adverse events and laboratory values 
during the first 24 weeks of treatment. Three pre-
specified, unblinded, interim reviews were con-
ducted by the committee: one when 25% of pa-
tients had completed 4 weeks of treatment, one 
when all patients had completed 12 weeks of treat-
ment, and one when 50% of patients had com-
pleted 24 weeks of treatment. After each review, 
the independent data and safety monitoring com-
mittee provided a summary report, without reveal-
ing the unblinded data, which was distributed to 
the clinical sites. The data management and inter-
im analyses were performed by the Duke Clinical 
Research Institute. A single statistical interim anal-
ysis, conducted by a statistical group that was inde-
pendent of the sponsor, was conducted after the 
last patient completed the week 36 visit. The anal-
ysis did not involve analysis of the primary end 
point; therefore, no adjustment to the two-sided, 
5% significance level was needed.
The study sponsor, Vertex Pharmaceuticals, and 
the academic principal investigators were jointly 
responsible for study design, protocol develop-
ment, study coordination, and drafting and review 
of previous drafts of the manuscript. A study pub-
lication committee, consisting of a majority of 
academic authors, agreed on a plan to submit the 
manuscript for publication. All authors had access 
to the data, vouch for the accuracy and complete-
ness of the data and analyses, and contributed 
to the writing of the manuscript.
Study Patients
Patients were enrolled at 53 international sites (41 
in the United States [including 1 in Puerto Rico], 
6 in Canada, 3 in the Netherlands, and 3 in Ger-
many). Eligible patients were 18 to 70 years of age, 
had chronic infection with HCV genotype 1, and 
had previously been treated for HCV infection with 
peginterferon alfa and ribavirin but did not have a 
sustained virologic response.
Patients’ previous response to at least 12 weeks 
of therapy with peginterferon alfa and ribavirin 
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was determined from medical records and records 
of previous HCV RNA levels and was defined as a 
nonresponse (i.e., undetectable HCV RNA levels 
never achieved during or at the end of the treat-
ment period), relapse (i.e., undetectable HCV RNA 
levels achieved during treatment for at least 42 
weeks but detectable HCV RNA levels observed 
during the follow-up period and lack of achieve-
ment of a sustained virologic response), or break-
through (i.e., undetectable HCV RNA levels dur-
ing the treatment period but detectable levels 
before the end of the treatment period).
Eligible patients were also seronegative for 
hepatitis B surface antigen and antibodies against 
human immunodeficiency virus types 1 and 2 and 
had an absolute neutrophil count of 1500 or more 
per cubic milliliter, a platelet count of 100,000 or 
more per cubic milliliter, and normal bilirubin 
values. Patients with decompensated liver disease, 
hepatocellular carcinoma, or other clinically sig-
nificant liver disease were excluded. A liver biopsy 
had to have been performed within 3 years be-
fore the study. The protocol was approved by the 
institutional review boards for all participating 
countries and study centers, and the study was 
performed according to Good Clinical Practice 
Guidelines. All patients provided written informed 
consent before participating in the study.
Study Design
This trial was a randomized, stratified, partially 
placebo-controlled, partially double-blind, phase 2 
study. Patients received one of four possible cours-
es of treatment.
The T12PR24 group received telaprevir (VX-950, 
Vertex Pharmaceuticals) plus peginterferon alfa-2a 
(Pegasys, Roche) and ribavirin (Copegus, Roche) 
for 12 weeks, followed by placebo and peginter-
feron alfa-2a and ribavirin for the next 12 weeks. 
The T24PR48 group received telaprevir plus pegin-
terferon alfa-2a and ribavirin for 24 weeks, fol-
lowed by peginterferon alfa-2a and ribavirin for 
the next 24 weeks. The T24P24 group received te-
laprevir and peginterferon alfa-2a for 24 weeks. 
The PR48 (control) group received placebo plus 
pegin terferon alfa-2a plus ribavirin for 24 weeks, 
followed by peginterferon alfa-2a and ribavirin for 
the next 24 weeks.
Telaprevir (an oral tablet) was given in a sin-
gle initial dose of 1125 mg, followed by a dose of 
750 mg every 8 hours thereafter during the pre-
defined treatment period. Peginterferon alfa-2a 
was administered at a dose of 180 μg each week, 
by means of subcutaneous injection. Ribavirin was 
administered twice daily at a dose of 1000 mg per 
day for patients weighing less than 75 kg and a 
dose of 1200 mg per day for patients weighing 
75 kg or more.
Randomization was stratified to balance race or 
ethnic group (black vs. nonblack) and previous vi-
rologic response (achievement or nonachievement 
of undetectable HCV RNA levels) among the four 
treatment groups. The enrollment was also lim-
ited such that neither of the two previous-response 
strata represented more than 60% of the overall 
study population. For the first 24 weeks, the treat-
ment assignments were double-blinded for patients 
in two of the three telaprevir groups (T12PR24 and 
T24PR48, but not T24P24). At week 24, patients 
in the T12PR24 group and those in the T24P24 
group ended treatment, and treatment continued, 
through week 48, for patients in the T24PR48 
group and those in the PR48 group. Patients ran-
domly assigned to retreatment with peg in ter fer-
on alfa-2a and ribavirin (the PR48 group) who did 
not have a sustained virologic response were sub-
sequently offered access to telaprevir, peg in ter fer-
on alfa-2a, and ribavirin, in a separate study.
Efficacy Assessments
Plasma HCV RNA levels were measured with the 
use of the COBAS TaqMan HCV assay, version 1.0 
(Roche Molecular Systems), with a lower limit of 
quantification of 30 IU per milliliter and a lower 
limit of detection of 10 IU per milliliter. Measure-
ments were obtained at various time points during 
the treatment period, which varied among the as-
signed treatments: on day 1 and at weeks 1, 2, 3, 
4, 8, 12, 16, 20, 24, 32, 36, 40, 44, and 48. All 
patients with undetectable HCV RNA levels (<10 
IU per milliliter) at the end of the treatment pe-
riod were followed to assess the durability of that 
response at weeks 4, 12, and 24 after the last 
dose. In addition, a 48-week assessment was per-
formed in patients in the telaprevir groups who 
completed the assigned treatment. HCV RNA re-
sults were double-blinded through week 24. How-
ever, an independent reviewer assessed the HCV 
RNA levels through week 24 and notified investi-
gators if patients met any of four criteria for dis-
continuation of all study drugs. These stopping 
rules were intended to prevent the continuation of 
treatment in patients who were unlikely to have a 
response to continued therapy.
The four stopping rules were as follows. The 
first was a stopping rule for breakthrough from 
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week 4 through week 24, stating that patients must 
discontinue all study drugs after a confirmed in-
crease in the HCV RNA level of more than 1 log10 
unit, as compared with the nadir, during week 4 
through week 24 of treatment or an HCV RNA 
level of more than 100 IU per milliliter in patients 
who had undetectable HCV RNA levels at a pre-
vious time point. The second was a stopping rule 
for nonresponse at week 4, stating that by week 
4 of treatment, patients in the PR48 group must 
have had a drop of at least 1 log10 unit in the HCV 
RNA level, as compared with the baseline level, 
and that patients in the other three groups must 
have had an HCV RNA level of less than 30 IU per 
milliliter. The third was a stopping rule for non-
response at week 12, stating that patients must 
have had a drop of at least 2 log10 units in the 
HCV RNA level, as compared with the baseline 
level, by week 12 of treatment. The fourth was a 
stopping rule for nonresponse at week 24, stating 
that patients in the T24PR48 and PR48 groups 
must have had an undetectable HCV RNA level 
by week 24 of treatment. All patients who met 
any of the four stopping rules were considered to 
have had nonresponse in the final analysis.
Safety Assessments
Safety assessments consisted of physical exami-
nations, recording of adverse events, and serum 
chemical and hematologic assessments at all study 
visits, including a safety follow-up visit, 14 days 
after the last dose of study drugs was adminis-
tered. Regarding adverse-event reporting, at each 
visit patients were asked to report any side effects 
they had had since the previous visit; these were 
reported on the case report forms. Twelve-lead elec-
trocardiography was performed at the screening 
visit and 2 weeks after the last dose of medication.
Statistical Analysis
The primary end point was a sustained virologic 
response, defined as an undetectable plasma HCV 
RNA level 24 weeks after the last dose of study 
drugs. The analysis included data for all patients 
who received at least one dose of study drugs. As-
suming a rate of sustained virologic response of 
45% in the telaprevir groups and 20% in the con-
trol group, we calculated that enrollment of ap-
proximately 110 patients in each of the four groups 
would be required for the study to have a statisti-
cal power of 90% to detect a significant difference 
in rates of sustained virologic response among the 
groups. Prespecified logistic-regression models 
were used to evaluate the relationship between 
response rates and treatment assignment, race or 
ethnic group, previous virologic response, base-
line HCV RNA level, HCV genotype, and age. Three 
other variables — sex, body-mass index, and pres-
ence or absence of cirrhosis — were added post 
hoc and were also explored.
R esult s
Study Patients
From February through June 2007, a total of 465 
patients were randomly assigned to a treatment 
group, and 453 received at least one dose of study 
drugs (Fig. 1). The baseline characteristics of the 
study patients were similar across the four treat-
ment groups, except for a significant difference in 
the median age (Table 1). The majority of patients 
(306 of 453 [68%]) were men, and the mean age 
was 51 years. A total of 89% of the study patients 
(402 of 453) were white. Most patients (418 of 453 
[92%]) had HCV RNA levels of 800,000 IU or more 
per milliliter at baseline. The majority of patients 
(265 of 453 [58%]) were infected with HCV geno-
type 1a. In total, 16% of the study population (74 
of 453 patients) had cirrhosis. In addition, 57% of 
patients (260 of 453) were classified as having 
had a nonresponse to previous HCV therapy, 36% 
(162 of 453) as having had a relapse, and 7% (31 of 
453) as having had a breakthrough.
Efficacy
The rate of the primary efficacy end point, a sus-
tained virologic response, was significantly high-
er in each of the three telaprevir groups — 51% in 
the T12PR24 group, 53% in the T24PR48 group, 
and 24% in the T24P24 group — than in the PR48 
group (14%; P<0.001, P<0.001, and P=0.02, re-
spectively) (Table 2).
Responses at the end of the treatment period 
were higher in the telaprevir groups than in the 
control group, as were the responses at week 4 
and week 12 (Table 2). All patients in the tel-
aprevir groups had a virologic response (a drop 
of at least 2 log10 units in the HCV RNA level, as 
compared with the baseline level) at week 12. 
Nine patients in the PR48 group had an early 
virologic response (at week 12). Rates of sus-
tained virologic response were higher among pa-
tients who had previously had a relapse than 
among those who had not had a response to pre-
vious treatment. The rates of sustained virologic 
response among patients with no previous re-
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sponse were 39% in the T12PR24 group, 38% in 
the T24PR48 group, and 11% in the T24P24 group, 
and the rates among patients with a previous re-
lapse were 69% in the T12PR24 group, 76% in the 
T24PR48 group, and 42% in the T24P24 group. In 
the PR48 group, the rates were 9% among patients 
with previous nonresponse and 20% among pa-
tients with a previous relapse.
Overall, relapse rates were 30% in the T12PR24 
group, 13% in the T24PR48 group, 53% in the 
T24P24 group, and 53% in the PR48 group. For 
the patients in the T12PR24 group who com-
pleted treatment, relapse rates were 28% overall, 
37% among patients with no previous response, 
and 18% among patients with a previous relapse. 
For patients in the T24PR48 group who com-
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Figure 1. Randomization and Sustained Virologic Response (SVR) among the Study Patients.
Of the 465 patients who underwent randomization (which was performed 5 to 7 days in adva ce of the start of dosing to allow time for 
shipment of study drugs to the site), 12 did not receive any study drugs: 5 withdrew consent between the time of randomization and day 
1, and 7 underwent randomization by mistake and were then withdrawn. Four protocol-defined virologic stopping rules were applied 
(see the Methods section). The stopping rules were met by a total of 151 patients: 17 in the T12PR24 group, 26 in the T24PR48 group,  
41 in the T24P24 group, and 67 in the PR48 group.
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pleted treatment, relapse rates were 4% overall, 
4% for patients with no previous response, and 0% 
for patients with a previous relapse.
Rates of viral breakthrough at week 24 were 
13% in the T12PR24 group, 12% in the T24PR48 
group, 32% in the T24P24 group, and 3% in the 
PR48 group. In all three telaprevir groups, the 
majority of patients with viral breakthrough had 
not had a previous response (Table 3). Most viral 
breakthroughs were observed during the first 12 
weeks of treatment. In the telaprevir groups, the 
rates of viral breakthrough were higher among 
Table 1. Baseline Characteristics of the Study Patients, According to Treatment Group.*
Characteristic T12PR24 (N = 115) T24PR48 (N = 113) T24P24 (N = 111) PR48 (N = 114)
Years of age — median (range) 51 (22–65) 52 (31–66) 53 (19–69) 50 (18–65)
BMI — median (range)† 27 (19–47) 28 (21–44) 27 (20–48) 28 (17–44)
Male sex — no. (%) 78 (68) 80 (71) 72 (65) 76 (67)
Race — no. (%)‡
White 103 (90) 99 (88) 100 (90) 100 (88)
Black 9 (8) 11 (10) 10 (9) 10 (9)
Asian 2 (2) 0 1 (1) 2 (2)
Other 1 (1) 3 (3) 0 2 (2)
Alanine aminotransferase — IU/liter 88±78 75±49 84±63 74±47
Total bilirubin — µmol/liter 12±6 11±5 11±5 11±5
Prothrombin time — sec 12±1 12±1 12±1 12±1
Serum albumin — g/liter 41±3 41±3 41±3 41±3
Platelet count — ×10−9/liter 217±76 208±65 211±67 215±61
HCV genotype 1 subtype — no. (%)§
1a 69 (60) 61 (54) 64 (58) 71 (62)
1b 33 (29) 42 (37) 36 (32) 34 (30)
Unknown 13 (11) 10 (9) 11 (10) 9 (8)
HCV RNA — log10 IU/ml¶ 6.7±0.5 6.7±0.6 6.7±0.5 6.6±0.5
HCV RNA ≥800,000 IU/ml — no. (%)¶ 106 (92) 104 (92) 104 (94) 104 (91)
Previous virologic response — no. (%)
Nonresponse 66 (57) 64 (57) 62 (56) 68 (60)
Breakthrough 7 (6) 8 (7) 11 (10) 5 (4)
Relapse 42 (37) 41 (36) 38 (34) 41 (36)
Stage of fibrosis and cirrhosis — no. (%)
None or minimal fibrosis 26 (23) 20 (18) 17 (15) 33 (29)
Portal fibrosis 44 (38) 40 (35) 40 (36) 37 (32)
Bridging fibrosis 26 (23) 33 (29) 32 (29) 31 (27)
Cirrhosis 19 (17) 20 (18) 22 (20) 13 (11)
* Plus–minus values are means ±SD. Patients were randomly assigned to one of the three telaprevir groups or to the control group. The con-
trol group, called the PR48 group, received peginterferon alfa-2a (180 µg per week) and ribavirin (1000 or 1200 mg per day, according to 
body weight) for 48 weeks, plus telaprevir-matched placebo for the first 24 weeks. The T12PR24 group received telaprevir (an initial dose of 
1125 mg and a dose of 750 mg every 8 hours thereafter) for 12 weeks, and then telaprevir-matched placebo for 12 weeks, with peginterferon 
alfa-2a and ribavirin, at the same dose as in the PR48 group, for 24 weeks. The T24PR48 group received telaprevir, at the same dose as in 
the T12PR24 group, for 24 weeks, with peginterferon alfa-2a and ribavirin, at the same dose as in the PR48 group, for 48 weeks. The T24P24 
group received telaprevir and peginterferon alfa-2a, at the same doses as in the other telaprevir groups, for 24 weeks. None of the listed 
characteristics were significantly different among the four groups, except for age (P = 0.01). To convert values for total bilirubin to milligrams 
per deciliter, divide by 17.1. HCV denotes hepatitis C virus.
† The body-mass index (BMI) is the weight in kilograms divided by the square of the height in meters.
‡ Race was self-reported.
§ HCV genotype and subtype were determined by means of the Trugene method (Bayer).
¶ HCV RNA levels were measured with the use of the COBAS TaqMan HCV assay (Roche), which has a lower limit of quantification of 30 IU 
per milliliter and a lower limit of detection of 10 IU per milliliter.
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Table 2. Rate of Undetectable Hepatitis C Virus (HCV) RNA Levels during and after the Treatment Period, According to 
Treatment Group.











Wk 2 25/115 (22) 22/113 (19) 12/111 (11) 0/114
Wk 4 70/115 (61) 56/113 (50) 52/111 (47) 0/114
Wk 12 86/115 (75) 74/113 (65) 59/111 (53) 9/114 (8)
End of treatment period
All patients 87/115 (76) 76/113 (67) 60/111 (54) 34/114 (30)
Patients who completed treatment 80/86 (93) 53/55 (96) 53/58 (91) 33/36 (92)
Patients who stopped treatment prematurely 7/29 (24) 23/58 (40) 7/53 (13) 1/78 (1)
24 Wk after end of treatment (sustained virologic  
response): primary end point
All patients* 59/115 (51) 60/113 (53) 27/111 (24) 16/114 (14)
Previous virologic response†
Nonresponse 26/66 (39) 24/64 (38) 7/62 (11) 6/68 (9)
Breakthrough 4/7 (57) 5/8 (62) 4/11 (36) 2/5 (40)
Relapse 29/42 (69) 31/41 (76) 16/38 (42) 8/41 (20)
Race‡
White 56/103 (54) 53/99 (54) 27/100 (27) 12/100 (12)
Black 2/9 (22) 6/11 (55) 0/10 1/10 (10)
Asian 1/2 (50) 0 0/1 2/2 (100)
Other 0/1 1/3 (33) 0 1/2 (50)
Fibrosis status§
No or minimal fibrosis 16/26 (62) 9/20 (45) 6/17 (35) 5/33 (15)
Portal fibrosis 23/44 (52) 25/40 (62) 9/40 (22) 6/37 (16)
Bridging fibrosis 10/26 (38) 17/33 (52) 8/32 (25) 4/31 (13)
Cirrhosis 10/19 (53) 9/20 (45) 4/22 (18) 1/13 (8)
Relapse among patients with undetectable HCV RNA 
at end of treatment period
All patients 26/87 (30) 10/76 (13) 32/60 (53) 18/34 (53)
Patients who completed treatment 22/80 (28) 2/53 (4) 28/53 (53) 17/33 (52)
Patients who stopped treatment prematurely 4/7 (57) 8/23 (35) 4/7 (57) 1/1 (100)
Previous virologic response†
Nonresponse 16/43 (37) 1/23 (4) 15/22 (68) 4/10 (40)
Breakthrough 0/4 1/5 (20) 1/5 (20) 0/2
Relapse 6/33 (18) 0/25 12/26 (46) 13/21 (62)
* The rate of sustained virologic response was significantly higher in the T12PR24 group, the T24PR48 group, and the 
T24P24 group than in the PR48 group (P<0.001, P<0.001, and P = 0.02, respectively).
† Previous virologic response to treatment with peginterferon alfa and ribavirin was classified as nonresponse (i.e., unde-
tectable HCV RNA levels never achieved during or at the end of the treatment period), breakthrough (i.e., undetectable 
HCV RNA levels during the treatment period but detectable levels before the end of the treatment period), or relapse 
(i.e., undetectable HCV RNA levels achieved during treatment for at least 42 weeks but detectable HCV RNA levels ob-
served during the follow-up period and lack of achievement of a sustained virologic response).
‡ Race was self-reported.
§ Analysis of virologic response according to fibrosis status was not prespecified in the protocol.
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patients infected with HCV genotype 1a (24%) 
than among patients infected with HCV genotype 
1b (11%). Most viral breakthroughs were associ-
ated with HCV variants with resistance to telapre-
vir, as previously observed in studies of patients 
who had not previously been treated.14,15
Logistic-regression analysis showed that a sus-
tained virologic response was significantly associ-
ated with assignment to the T12PR24 or T24PR48 
group, an undetectable HCV RNA level during a 
previous period of treatment with peginterferon 
alfa and ribavirin, and low baseline viral load 
(<800,000 IU per milliliter).
With the exception of one patient who was lost 
to follow-up, in all patients who completed a tel-
aprevir regimen and who had a sustained viro-
logic response 24 weeks after the end of the 
treatment period, the virologic response was main-
tained at 48 weeks. Seven of 14 patients in the 
three telaprevir groups who prematurely discon-
tinued treatment and had a sustained virologic 
response also underwent a follow-up assessment 
of the viral level at week 48. In these seven pa-
tients, the virologic response was maintained 48 
weeks after the end of treatment.
Safety
Several of the most common adverse events, such 
as fatigue and influenza-like symptoms, were 
consistent with typical interferon-related system-
ic symptoms (Table 4). However, rash and pruri-
tus were more common in the groups that re-
ceived telaprevir than in the PR48 group; rash 
and pruritus were also reported in earlier studies 
of patients who had not previously been treat-
ed.14,15 The overall incidence of any rash-related 
event was 50% in the T12PR24 group and 60% in 
the T24PR48 group, as compared with 20% in the 
PR48 group. The severity of the rash was also 
greater in the T12PR24 and T24PR48 groups than 
in the PR48 group.
In general, the rashes in patients in the tel-
aprevir groups were described as maculopapular. 
The median time to the appearance of a rash of 
any severity in the telaprevir groups was 7 to 28 
days. Severe (grade 3) rash was found in 5% of 
patients in the T12PR24 group, 4% in the T24PR48 
group, 3% in the T24P24 group, and 0% in the 
control group. Eighteen patients in the telaprevir 
groups (5%), but none of those in the control 
group, discontinued treatment because of rash. 
Rash was monitored during the treatment period; 
medications including topical antiallergic agents 
and topical and systemic antipruritic agents were 
allowed, at the investigator’s discretion, for all 
grades of rash. If discontinuation of study medi-
cation was indicated, both ribavirin and telapre-
vir were stopped while patients continued to re-
ceive peginterferon alfa-2a. The median time to 
treatment discontinuation because of rash in the 
telaprevir groups was 51 to 64 days (range, 4 to 
123) after the start of treatment. Severe rashes 
resolved in 12 of 14 patients within 9 to 104 days 
after onset; follow-up data were not available for 
2 patients; 6 patients had severe rash necessitat-
ing corticosteroid treatment; and 1 was hospital-
ized for severe rash.
Patients who received telaprevir-based therapy 
were more likely to discontinue treatment because 
of an adverse event (50 of 339 [15%]) than were 
controls, who received peginterferon alfa-2a and 
ribavirin alone (5 of 114 [4%]). Skin disorders 
were the most frequent cause of discontinuation 
among the telaprevir groups (accounting for 22 
of the 50 patients who discontinued treatment).
Changes in laboratory values during the study 
were consistent with those reported in associa-
tion with the use of peginterferon alfa and riba-
virin. A decrease in hemoglobin levels was more 
common in patients receiving telaprevir-based 
regimens than in controls (Fig. 2) and reversed 
on discontinuation of telaprevir. Treatment with 
erythropoietin-stimulating agents was prohibited 
during the course of the study.
Discussion
The results of this study show a benefit of tel-
aprevir in patients who had not had a sustained 
virologic response to an initial, full course of 
peginterferon alfa and ribavirin. As in previous 
studies in untreated patients, a higher break-
through rate (32%), higher relapse rate (53%), and 
lower sustained virologic response rate (24%) 
were observed in the T24P24 group as compared 
with the T12PR24 group and the T24PR48 group, 
again demonstrating the necessity for inclusion 
of ribavirin in combination with telaprevir and 
peginterferon alfa.14 Patients’ previous response 
to peginterferon alfa and ribavirin also appeared to 
influence their response to combined treatment 
with telaprevir. Those who had previously been 
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documented as having clearing of HCV RNA dur-
ing therapy and who subsequently had a relapse 
were the most likely to have a response to tel-
aprevir plus peginterferon alfa-2a and ribavirin 
(69 to 76% of these patients had a sustained viro-
logic response). Those with a previous nonre-
sponse were less likely to have a response after 
retreatment, but in this subgroup of patients, the 
observed response rates of 38% in the T24PR48 
group and 39% in the T12PR24 group are the 
highest reported to date and more than four times 
the response rate in the control group (9%). Re-
sults should be interpreted with caution for pa-
tients of African, Hispanic, or Asian ancestry, 
since only a small number of such patients were 
included in this study.
Viral breakthrough rates were 12 to 13% in 
patients receiving telaprevir and peginterferon 
alfa-2a with ribavirin. Viral breakthrough was 
more common in the absence of ribavirin, oc-
curred early during therapy, was more common 
in patients who had not had a response to previ-
ous therapy than in patients who had had a re-
lapse after previous therapy, and was more fre-
quently observed in patients infected with HCV 
genotype 1a, as previously reported in patients 
who had not been treated.14,15 Among patients 
who had viral breakthrough during the treatment 
period, sequencing analysis revealed HCV vari-
ants with substitutions at the NS3 protease amino 
acids 36, 54, 155, and 156, findings that are 
similar to those in patients who had not previ-
ously been treated and who had viral break-
through while receiving telaprevir. The majority 
of patients who discontinued therapy because of 
a stopping rule had the V36M/R155K double vari-
Table 3. Cumulative Rates of Hepatitis C Virus (HCV) Breakthrough during the Treatment Period, According to 
Treatment Group.*
Previous Virologic Response† T12PR24 (N = 115) T24PR48 (N = 113) T24P24 (N = 111) PR48 (N = 114)
number of patients/total number (percent)
Week 4
Nonresponse 2/66 (3) 6/64 (9) 18/62 (29) 0/68
Breakthrough 0/7 0/8 1/11 (9) 0/5
Relapse 0/42 0/41 0/38 0/41
Week 8
Nonresponse 8/66 (12) 9/64 (14) 23/62 (37) 0/68
Breakthrough 0/7 0/8 1/11 (9) 0/5
Relapse 1/42 (2) 0/41 2/38 (5) 0/41
Week 12
Nonresponse 8/66 (12) 9/64 (14) 26/62 (42) 0/68
Breakthrough 0/7 0/8 1/11 (9) 0/5
Relapse 1/42 (2) 0/41 2/38 (5) 0/41
Week 24
Nonresponse 13/66 (20) 14/64 (22) 28/62 (45) 2/68 (3)
Breakthrough 1/7 (14) 0/8 3/11 (27) 0/5
Relapse 1/42 (2) 0/41 5/38 (13) 1/41 (2)
Week 48
Nonresponse NA 15/64 (23) NA 2/68 (3)
Breakthrough NA 0/8 NA 0/5
Relapse NA 1/41 (2) NA 1/41 (2)
* Viral breakthrough was monitored from week 4 through week 24 or 48 in the current study and was defined as an in-
crease in the HCV RNA level of more than 1 log10 unit, as compared with the nadir, or an HCV RNA level of more than 
100 IU per milliliter in patients who had undetectable HCV RNA levels (<10 IU per milliliter) at a previous time point.
† Previous virologic response to treatment with peginterferon alfa and ribavirin was classified as nonresponse (i.e., unde-
tectable HCV RNA levels never achieved during or at the end of the treatment period), breakthrough (i.e., undetectable 
HCV RNA levels during the treatment period but detectable levels before the end of the treatment period), or relapse 
(i.e., undetectable HCV RNA levels achieved during treatment for at least 42 weeks but detectable HCV RNA levels ob-
served during the follow-up period and lack of achievement of a sustained virologic response).
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Table 4. Reasons for Discontinuation of Study Drugs and Incidence of the Most Common Adverse Events,  










number of patients (percent)
Discontinuation
Reason for discontinuation
Any 29 (25) 58 (51) 53 (48) 78 (68)
Any stopping rule except viral breakthrough 5 (4) 18 (16) 28 (25) 66 (58)
Viral breakthrough 12 (10) 8 (7) 13 (12) 1 (1)
Adverse event 11 (10) 29 (26) 10 (9) 5 (4)
Skin-related, including rash 6 (5) 9 (8) 7 (6) 3 (3)
Anemia 0 2 (2) 1 (1) 1 (1)
Other or lost to follow-up 1 (1) 3 (3) 2 (2) 6 (5)
Adverse events
Severe adverse event 19 (17) 27 (24) 20 (18) 13 (11)
General disorder
Fatigue 77 (67) 69 (61) 51 (46) 64 (56)
Influenza-like illness 29 (25) 36 (32) 28 (25) 36 (32)
Irritability 20 (17) 27 (24) 16 (14) 25 (22)
Pyrexia 16 (14) 27 (24) 16 (14) 14 (12)
Chills 17 (15) 23 (20) 17 (15) 15 (13)
Gastrointestinal disorder
Nausea 41 (36) 54 (48) 27 (24) 39 (34)
Diarrhea 37 (32) 49 (43) 29 (26) 22 (19)
Hemorrhoids 15 (13) 19 (17) 14 (13) 3 (3)
Skin and subcutaneous tissue disorders
Pruritus 39 (34) 50 (44) 40 (36) 17 (15)
Any rash-related event 58 (50) 68 (60) 46 (41) 23 (20)
Alopecia 24 (21) 16 (14) 14 (13) 13 (11)
Nervous system disorders
Headache 51 (44) 39 (35) 40 (36) 41 (36)
Dizziness 10 (9) 20 (18) 17 (15) 18 (16)
Psychiatric disorders
Insomnia 33 (29) 30 (27) 20 (18) 19 (17)
Depression 13 (11) 17 (15) 13 (12) 19 (17)
Musculoskeletal disorders
Myalgia 25 (22) 16 (14) 19 (17) 21 (18)
Arthralgia 14 (12) 22 (19) 15 (14) 21 (18)
Respiratory disorders
Cough 15 (13) 22 (19) 9 (8) 20 (18)
Blood and lymphatic system disorders
Anemia 30 (26) 30 (27) 9 (8) 9 (8)
* The adverse events listed are those that were reported in at least 15% of patients in at least one of the four study 
groups; events of all grades are included. Events in bold are those for which one or more of the three telaprevir groups 
had an incidence that was 10 percentage points higher than that in the PR48 group.
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ant; all but one of the patients had infection with 
HCV genotype 1a. Relapse rates were substantially 
lower when telaprevir was added to the retreat-
ment regimen, as in previous studies.14,15 Relapse 
occurred less frequently with the T24PR48 regi-
men than with the T12PR24 regimen. As in other 
studies of telaprevir, rates of discontinuation due 
to side effects were higher among patients receiv-
ing the three-drug combination, and for those 
patients, discontinuation was most commonly due 
to rash.
Rates of sustained virologic response were 
similar in the T12PR24 and T24PR48 groups, and 
discontinuation of treatment due to adverse events 
was less common in the T12PR24 group than in 
the T24PR48 group. Therefore, the overall efficacy 
and safety results indicate that the T12PR24 regi-
men appeared to provide a better risk–benefit 
profile than the T24PR48 regimen. The higher 
discontinuation rates and the lower relapse rates 
in the T24PR48 group than in the T12PR24 
group suggest that an optimal retreatment regi-
men may consist of a shorter period of treatment 
with telaprevir combined with a longer period of 
treatment with peginterferon alfa and ribavirin. 
Erythropoietin-stimulating agents were not per-
mitted in this study; however, anemia was more 
frequently observed in patients who received a 
telaprevir-based regimen. The study design did not 
address other possible treatment options, such as 
12 weeks of telaprevir plus 48 weeks of peginter-
feron alfa-2a and ribavirin.
In conclusion, this phase 2 study showed that 
the addition of telaprevir to current therapy as a 
retreatment strategy in HCV-infected patients who 
had not had a sustained response to previous 
therapy significantly increased the likelihood of 
eradication of HCV infection.
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Figure 2. Median Hemoglobin Values during the Treatment Period, Accord-
ing to Treatment Group.
At each time point, data are shown for all patients whose hemoglobin as-
sessment was available. The duration of treatment with telaprevir is indicat-
ed by the gray bars. At the safety follow-up visit, 14 days after the last dose 
of study drugs was administered, the median hemoglobin levels were simi-
lar in all four treatment groups. RBV denotes ribavirin.
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